BioArctic AB (OSTO:BIOA B)
kr 238.4 5 (2.14%) Market Cap: 21.06 Bil Enterprise Value: 20.57 Bil PE Ratio: 0 PB Ratio: 21.21 GF Score: 55/100

Q2 2023 BioArctic AB Earnings Call Transcript

Jul 12, 2023 / 07:30AM GMT
Release Date Price: kr291.4 (+0.48%)
Operator

Welcome to the BioArctic Q2 Presentation for 2023. (Operator Instructions)

Now, I will hand the conference over to the CEO, Gunilla Osswald; and CFO, Anders Martin-Löf. Please go ahead.

Gunilla Osswald;publ;CEO
BioArctic AB

()-

Good morning, and welcome to BioArctic's presentation for the second quarter of 2023. I am Gunilla Osswald, and I'm the CEO of BioArctic, and I will share today's presentation with our CFO, Anders Martin-Löf.

I think it's very exciting times for BioArctic with LEQEMBI now granted full approval by the FDA last week and with CMS announcing a broader reimbursement. It's a beginning of a new era and BioArctic is behind this true breakthrough in the treatment of Alzheimer's disease. We can now help a large number of patients and their families, and I think that is extremely gratifying. And of course, I will talk more about LEQEMBI here today.

Next slide, please. BioArctic is listed at Nasdaq Stockholm Large Cap since January this year, and this is our disclaimer.

Next

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot